| The Effects of Alendronate on Bone Mineral Density and Bone Turnover Markers
in Postmenopausal Osteoporosis Women
|
| 골다공증을 가진 폐경기 후 여성에서 알렌드로네이트 치료에
의한 골밀도 및 골표지자의 변화
|
| 황준영,조호찬,류성열,신동우,이동욱,이상준,강효경*,김소연*,이인규 |
| 계명대학교 의과대학 내과학교실, 의과학연구소* |
|
|
| Abstract |
Background
Alendronate and hormone replacement therapies are very effective in the treatment of postmenopausal women with osteoporosis. But, there were few datas about alendronate treatment in Korea. We evaluated the effect of alendronate therapy on bone mass and compared the effectivity in between the group with alendronate treatment alone and the group with alendronate-tibolone combination treatment.
Methods
A total 30 postmenopausal women with osteoporosis, who had no history of special drug treatment for osteoporosis, were recruited for this study. 10 women received daily alendronate 10 mg (Group I), 10 women received daily alendronate 10 mg and tibolone 2.5 mg (Group II), and 10 women received daily calcitriol 0.5 g (Group III). Changes in bone mineral density (BMD) and biochemical markers of bone turnover were assessed before and after 6 months of treatment.
Results
In group I and II, average L2-L4 bone mineral density was significantly increased by 6.2±2.3% and 7.8±2.5% (p<0.01, in both groups) after treatment. But, in group III, percent change in BMD was not significant (0.5±2.2%, p=0.475). Biochemical markers of bone turnover (alkaline phosphatase, osteocalcin) decreased significantly at 6 months in all three groups.
Conclusion
Alendronate and alendronate-tibolone combination therapies are significantly increased bone mineral density and decreased bone resorption. These therapies seemed to be very effective in the treatment of postmenopausal women with osteoporosis.
|
| Key Words:
Alendronate, Tibolone, Bone mineral density, Postmenopausal, Osteoporosis |
|
PDF Links
Full text via DOI
Download Citation
